Paolo Pucci and Nicholas Vahanian Appointed to Board of Directors of NewLink Genetics
13 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 13, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Supports 2015 World Pancreatic Cancer Day
10 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics Corporation Announces Promising Clinical Data on Indoximod at the Society for Neuro-Oncology Annual Meeting
09 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 09, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Provides Operational Update and Reports Third Quarter 2015 Financial Results
03 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 03, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics to Participate in Three Upcoming Investor Conferences
30 oct. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Oct. 30, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics to Host Its Third Quarter 2015 Earnings Conference Call on November 3, 2015
23 oct. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Oct. 23, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing novel immuno-oncology and infectious-disease...
New Study Published in Cell Reports Highlights Indoximod, Demonstrates the Key Role of IDO in Both Local and Systemic Immunosuppression
13 oct. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Oct. 13, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics Awarded $18 Million Contract Option from BARDA
01 oct. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Oct. 01, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United...
NewLink Genetics Corporation Announces Promising Clinical Data at European Cancer Congress 2015 (ECC)
27 sept. 2015 10h45 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Sept. 27, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Announces Promising Phase 1b Data From the Combination of Indoximod and Ipilimumab in Melanoma at European Cancer Congress 2015 (ECC)
26 sept. 2015 10h45 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Sept. 26, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...